UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating

Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS analyst Trung Huynh raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $326 from $315 while keeping a Neutral rating on the shares.

Dogs of the Dow: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick

A pharmacist filling a prescription for a complex drug developed by the company.

The firm told investors in a research note that it expects Amgen Inc. to deliver a small beat in its Q2 results after two consecutive solid quarterly beats. However, it also continues to believe that the rare disease products may be bumpy.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.